Cancer Risk After Iodine-131 Therapy for Hyperthyroidism

Lars‐Erik Holm, Peter Hall, K Wiklund, +12

JNCI Journal of the National Cancer Institute

What margins should be added to the clinical target volume in radiotherapy treatment planning for lung cancer?

Lars Ekberg, Ola Holmberg, Lena Wittgren, +2

Radiotherapy and Oncology

Radiation TherapyMedicineRadiotherapy Treatment PlanningClinical Target VolumeTreatment Planning +6

Cancer mortality after iodine‐131 therapy for hyperthyroidism

Per Hall, Gertrud E. B. Berg, Göran Bjelkengren, +8

International Journal of Cancer

Cancer RiskMedicineIodine Deficiency DisordersThyroid DiseaseIodine‐131 Therapy +13

Cancer risks in thyroid cancer patients

Per Hall, Lotte Holm, G. E. F. Lundell, +6

British Journal of Cancer

Cancer RiskMedicineThyroid DiseaseThyroid Cancer PatientsThyroid Hormone +4

Thyroid Cancer After Diagnostic Doses of Iodine-131: A Retrospective Cohort Study

Lars‐Erik Holm, K Wiklund, G. E. F. Lundell, +9

JNCI Journal of the National Cancer Institute

Epidemiology Of CancerPathologyCancer RegistrationOncologyIodine Deficiency Disorders +16

Number of patients potentially eligible for proton therapy

Bengt Glimelius, Anders Ask, Göran Bjelkengren, +5

Acta Oncologica

PharmacotherapyParticle TherapyMedical TreatmentClinical PopulationBrachytherapy +17

Dacarbazine–vindesine versus dacarbazine–vindesine–cisplatin in disseminated malignant melanoma. A randomised phase III trial

Ulf Jungnelius, Ulrik Ringborg, S. Aamdal, +10

European Journal of Cancer

OncologyMedicineDisseminated Malignant MelanomaDacarbazine–vindesine Versus Dacarbazine–vindesine–cisplatinMelanoma +6

Oral implant rehabilitation in irradiated patients without adjunctive hyperbaric oxygen.

Gunilla Andersson, Lars Andréasson, Göran Bjelkengren

PubMed

Oral Implant RehabilitationEarly StageMedicineBrånemark ImplantsBrachytherapy +11

Cancer Risk in Population Examined With Diagnostic Doses of 131I

Lars‐Erik Holm, K Wiklund, G. E. F. Lundell, +8

JNCI Journal of the National Cancer Institute

Epidemiology Of CancerPathologyOncologyDiagnostic DosesPublic Health +15

A phase II study of combined 5-fluorouracil and mitomycin C in advanced breast cancer

W. Mattsson, F. Von Eyben, L. Hallsten, +1

Cancer

Advanced Breast CancerBreast OncologyMitomycin CMedicinePharmacology +10